Prudential Financial’s Protagonist Therapeutics PTGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$10M Sell
95,235
-15,125
-14% -$1.34M 0.01% 631
2025
Q4
$9.64M Sell
110,360
-16,043
-13% -$1.31M 0.01% 636
2025
Q3
$8.4M Buy
126,403
+48,995
+63% +$2.78M 0.01% 697
2025
Q2
$4.28M Buy
77,408
+19,050
+33% +$914K 0.01% 1004
2025
Q1
$2.82M Sell
58,358
-1,640
-3% -$68.7K ﹤0.01% 1127
2024
Q4
$2.32M Sell
59,998
-800
-1% -$34.9K ﹤0.01% 1233
2024
Q3
$2.74M Buy
+60,798
New +$2.46M ﹤0.01% 1297
2023
Q2
Sell
-67,293
Closed -$1.55M 2691
2023
Q1
$1.55M Buy
+67,293
New +$1.13M ﹤0.01% 1497
2022
Q2
Sell
-22,993
Closed -$544K 2735
2022
Q1
$544K Sell
22,993
-7,112
-24% -$200K ﹤0.01% 2168
2021
Q4
$1.03M Sell
30,105
-190
-0.6% -$6.01K ﹤0.01% 1867
2021
Q3
$537K Buy
30,295
+450
+2% +$19.2K ﹤0.01% 2117
2021
Q2
$1.34M Sell
29,845
-3,770
-11% -$124K ﹤0.01% 1677
2021
Q1
$871K Sell
33,615
-10,210
-23% -$258K ﹤0.01% 1898
2020
Q4
$884K Sell
43,825
-11,190
-20% -$241K ﹤0.01% 1810
2020
Q3
$1.08M Sell
55,015
-12,290
-18% -$231K ﹤0.01% 1609
2020
Q2
$1.19M Sell
67,305
-5,035
-7% -$63.2K ﹤0.01% 1572
2020
Q1
$511K Buy
72,340
+20,650
+40% +$155K ﹤0.01% 1905
2019
Q4
$365K Buy
+51,690
New +$513K ﹤0.01% 2149
2018
Q3
Sell
-12,100
Closed -$81K 2463
2018
Q2
$81K Sell
12,100
-1,470
-11% -$11.3K ﹤0.01% 2398
2018
Q1
$116K Buy
+13,570
New +$256K ﹤0.01% 2290

Other funds holding PTGX

Prudential Financial's PTGX Position: Q1 2026 in Review

Prudential Financial reduced its Protagonist Therapeutics (PTGX) stake by 14% in Q1 2026, selling an estimated $1.34M and leaving 95,235 shares worth $10M. The position accounts for 0.01% of the portfolio, ranked #631.

Prudential Financial first reported a position in PTGX in Q1 2018 and has held it in 20 quarters since. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • Prudential Financial held 95,235 shares of Protagonist Therapeutics worth $10M as of Q1 2026.
  • Prudential Financial sold 15,125 Protagonist Therapeutics shares in Q1 2026, an estimated $1.34M.
  • Protagonist Therapeutics made up 0.01% of Prudential Financial's portfolio in Q1 2026, its #631 holding.
  • Prudential Financial first reported a position in Protagonist Therapeutics in Q1 2018 and has held it in 20 quarters since.
  • 317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Prudential Financial's 13F filing for Q1 2026, filed 13 May 2026.